Intra-arterial thrombolysis in 24 consecutive patients with internal carotid artery T occlusions

J Neurol Neurosurg Psychiatry. 2003 Jun;74(6):739-42. doi: 10.1136/jnnp.74.6.739.

Abstract

Objectives: To determine the safety, efficacy, and predictors of favourable outcome of intra-arterial thrombolysis in acute stroke attributable to internal carotid "T"occlusion

Methods: The authors analysed 24 consecutive patients with T occlusions of the internal carotid artery treated by local intra-arterial thrombolysis using urokinase.

Results: The median baseline National Institutes of Health Stroke Scale was 19. The average time from symptom onset to treatment was 237 minutes. Four patients (16.6%) had a favourable (modified Rankin Scale score (mRS</=2)) and 10 patients (41.7%) a poor outcome (mRS 3 or 4) after three months. Ten patients (41.7%) died. One symptomatic intracerebral haemorrhage (4.2%) occurred. Partial recanalisation of the intracranial internal carotid artery was achieved in 15 (63%), of the middle cerebral artery in four (17%), and of the anterior cerebral artery in eight patients (33%). Complete recanalisation never occurred. Sufficient leptomeningeal collaterals as seen on arteriography (p=0.02) and age <60 years (p=0.012) were the only predictors of favourable clinical outcome.

Conclusions: Acute stroke attributable to carotid T occlusion remains a condition with a generally poor prognosis even when intra-arterial thrombolysis is performed. Favourable outcome was seen only in patients with sufficient leptomeningeal collaterals.

Publication types

  • Review

MeSH terms

  • Adult
  • Aged
  • Carotid Artery Thrombosis / diagnostic imaging
  • Carotid Artery Thrombosis / drug therapy*
  • Cerebral Angiography / methods
  • Female
  • Humans
  • Infusions, Intra-Arterial
  • Male
  • Middle Aged
  • Plasminogen Activators / administration & dosage
  • Plasminogen Activators / therapeutic use*
  • Surveys and Questionnaires
  • Thrombolytic Therapy*
  • Treatment Outcome
  • Urokinase-Type Plasminogen Activator / administration & dosage
  • Urokinase-Type Plasminogen Activator / therapeutic use*

Substances

  • Plasminogen Activators
  • Urokinase-Type Plasminogen Activator